Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Total and Ionized Magnesium Kinetics During Citrate-Anticoagulated Continuous Renal Replacement Therapy

NCT07906340 is registered in ClinicalTrials.gov with Region Skane as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07906340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Total and Ionized Magnesium Kinetics During Citrate-Anticoagulated Continuous Renal Replacement Therapy
Lead sponsor
Region Skane
Phase
Observational
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
January 31, 2028
Enrollment
35 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

continuous renal replacement therapy (crrt), magnesium

Primary endpoints

Registered primary outcome measures; 5 primary.

  • Changes in systemic total magnesium concentration Before CRRT initiation (baseline) and at 2, 6, 12, 18, 24, 48, and 72 hours after initiation.

    Changes in systemic total magnesium concentration (mmol/L), measured using conventional clinical laboratory methods, will be assessed from baseline and over time during continuous renal replacement therapy with regional citrate anticoagulation.

  • Changes in systemic ionized magnesium concentration Before CRRT initiation (baseline) and at 2, 6, 12, 18, 24, 48, and 72 hours after initiation.

    Changes in systemic ionized magnesium concentration (mmol/L), measured using ion-selective electrode technology, will be assessed from baseline and over time during continuous renal replacement therapy with regional citrate anticoagulation.

  • Citrate-associated changes in magnesium ionization At 2, 6, 12, 18, 24, 48, and 72 hours after CRRT initiation.

    Changes in the ionized magnesium fraction (ionized magnesium/total magnesium) between systemic and pre-filter blood will be assessed following administration of citrate-containing predilution fluid, accounting for dilution. Ionized magnesium will be measured using ion-selective electrode technology and total magnesium using conventional clinical laboratory methods.

  • Magnesium flux across the extracorporeal filter At 2, 6, 12, 18, 24, 48, and 72 hours after CRRT initiation.

    Magnesium flux across the extracorporeal filter (mmol/h) will be calculated using total and ionized magnesium concentrations in pre-filter and post-filter blood and effluent fluid, accounting for blood flow rates, treatment fluid flow rates and fluid composition. Ionized magnesium will be measured using ion-selective electrode technology and total magnesium using conventional clinical laboratory methods.

  • Net magnesium loss attributable to CRRT At 2, 6, 12, 18, 24, 48, and 72 hours after CRRT initiation.

    Net magnesium loss attributable to CRRT (mmol/h) will be calculated from magnesium removal in the effluent, accounting for magnesium supplied through dialysate and post-filter replacement fluids. Calculations will use the actual treatment fluid composition and flow rates at each sampling time. Ionized magnesium will be measured using ion-selective electrode technology and total magnesium using conventional clinical laboratory methods.

Lead sponsor's other trials

Region Skane, most recent start first.